Sedef, Ali MuratKose, FatihDogan, OzlemErgun, TarkanSezer, AhmetMertsoylu, HoseyinMuallaoglu, SadikBesen, AyberkOzyilkan, Ozgur2019-12-062019-12-0620152049-9450https://www.spandidos-publications.com/mco/3/2/400http://hdl.handle.net/11727/4367Soft tissue sarcomas (STS) are a group of rare mesenchymal cancers that include approximately 50 histological types and account for 1% of all adult cancers. The standard curative treatment option for localized disease is surgical resection and, if a surgically removed tumor exhibits high-risk characteristics, adjuvant chemotherapy and radiotherapy may be administered. Sarcoma presenting at an advanced stage has a dismal prognosis and survival has not markedly improved over the last 20 years. The standard first-line treatment for advanced STS, other than gastrointestinal stromal tumors, is cytotoxic chemotherapy. Therapies targeting pro-angiogenic factors have been a focus of drug development for STS over the last few years. Pazopanib, a multitargeted tyrosine kinase inhibitor, is a novel treatment option for patients with metastatic STS in the second-line setting. This is a presentation of 2 case reports of patients with metastatic STS who responded well to treatment with pazopanib.enginfo:eu-repo/semantics/openAccessresponse ratepazopanibmetastatic soft tissue sarcomastargeted therapyarticle32400402000453153900024